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Abstract
Background: There is evidence that impaired metabolism play an important role in the etiology of many
neuropsychiatric disorders. Although this has not been investigated to date, several recent studies proposed that
nitrogen metabolism-related parameters may have a pathophysiological role in autism.
Methods: The study enrolled 20 Saudi boys with autism aged 4 to 12 years and 20 healthy controls matched for
age and gender. Levels of creatine, urea, ammonia, gamma-aminobutyric acid (GABA), glutamate:glutamine (Glu:
Gln) ratio, and enzymatic activities of glutamate dehydrogenase, 5’-nucleotidase, and adenosine deaminase (ADA)
were determined in plasma samples from both groups.
Results: We found a significant elevation of creatine, 5’-nucleotidase, GABA, and glutamic acid and a significant
decrease in the enzymatic activity of ADA and glutamine level in patients with autism compared with healthy
controls. The most significant variation between the two groups was found in the Glu:Gln ratio.
Conclusion: A raised Glu:Gln ratio together with positive correlations in creatine, GABA, and 5’-nucleotidase levels
could contribute to the pathophysiology of autism, and might be useful diagnostic markers. The mechanism
through which these parameters might be related to autism is discussed in detail.
Background
Autism is a complex disorder that is heterogeneous in
nature, with varying degrees of severity, and for which
no specific biological marker has been identified. A
recent epidemiological study in Saudi Arabia established
the autism prevalence at 6:1000 (Talat; unpublished
data, personal communication). The increasing preva-
lence of autism is raising public-health concerns [1]. As
indicated by several biological parameters, a hallmark of
autism is its substantial heterogeneity. Although the
core deficits may fall in the similar domains, no two
people with autism have exactly the same profile. Such a
wide range of clinical features makes the diagnosis and
treatment of autism very challenging. The overlapping
of different biological and genetic etiologies and the
individual variations in patients with autism makes it
difficult to establish unified diagnostic biomarkers and
therapeutic strategies [2,3].
Autism involves many metabolic derangements, such
as those involving the trans-sulfation pathway that
synthesizes cysteine, glutathione, sulfate, and taurine.
Abnormalities also include an imbalance between antiox-
idation systems and production of reactive oxygen spe-
cies, which results in disruption of cellular molecules and
subsequent damage. In addition, a role for mild mito-
chondrial dysfunction in autism has been suggested [4-6].
Nitrogen metabolism and nitrogen compounds are
important and essential components in the life-cycle of
living organisms, The simplest useful form of nitrogen is
ammonia, which only a few organisms can synthesize
from atmospheric nitrogen. Therefore, amino groups are
carefully husbanded in nature. Nitrogen greatly contri-
butes to the mass and composition of biological systems,
with most of it being in the form of amino acids. During
metabolic turnover of proteins and nucleic acids, nitro-
gen-containing molecules are often salvaged and reused
[7].
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enzymes, carbamoyl phosphate synthetase (CPS)-1 and
ornithine transcarbamylase (OTC), and is therefore
unable to remove nitrogen as urea. The main route for
ammonia disposal in the brain is via glutamine synthesis
from glutamate by glutamate synthase (GS) in astro-
cytes. In neurons, glutamine can be deaminated to glu-
tamate by glutaminase. The generated ammonia then
escapes through the extracellular space into astrocytes
to participate in the GS reaction. This creates a gln-glu
cycle between neurons and astrocytes [8]. Another
important but minor route for disposal of ammonia is
amination of a-ketoglutarate (a-KG) to glutamate by
glutamate dehydrogenase (GDH) [7]. In addition to their
crucial energetic roles in the CNS, ATP and adenosine
are important in neurotransmission. Adenosine is a neu-
romodulator of brain function that is uniquely posi-
tioned to integrate excitatory and inhibitory
neurotransmission [9]. Adenosine metabolism in the
brain is very important, and its dysregulation has been
implicated in several neurological disorders. Intracellular
and extracellular levels of adenosine are tightly con-
trolled by specific nucleoside transporters and several
important enzymes, which include adenosine deaminase
(ADA) and 5’-nucleotidase (5’-NT) [10-12].
Nitric oxide (NO) is a neurotransmitter and/or neuro-
modulator in both the central and peripheral nervous
systems. In the CNS, it is associated with pain percep-
tion and control of sleep, appetite, thermoregulation,
learning and memory, neural development, and synaptic
plasticity. Depending on its concentration, NO exerts a
biphasic effect on the release of several neurotransmit-
ters and neuromodulators, including glutamate, gamma-
aminobutyric acid (GABA), serotonin (5-HT), with low
concentrations decreasing their release and high concen-
trations increasing release [13].
The crucial role of creatine (Cr) and phosphorylcrea-
tine (PCr) as components of the CK system to maintain
energy requirements is well established. However, Cr is
thought to have additional important functions in the
CNS [14]. For example, recent findings suggest a neuro-
protective role of Cr against ammonia toxicity, prevent-
ing impairment of axonal growth [15]. Cr is also
involved in regulation of glycolysis, stabilization of mito-
chondrial creatine kinase (mtCK), and inhibition of
mitochondrial permeability transition pore (MPTP)
opening, an early event in apoptosis [16].
Based on these findings, we aimed in the present
study to measure a number of selected biochemical
parameters related to nitrogen metabolism in the plasma
of patients with autism from Saudi Arabia, and com-
pared these with the levels in healthy controls matched
for age and gender.
Methods
Ethics approval
The study protocol followed the ethical guidelines of the
most recent Declaration of Helsinki [17]. Written
informed consent provided by the parents of all subjects
enrolled in the study according to the guidelines of the
ethical committee of King Khalid Hospital, King Saud
University, and assent to participate was obtained from
the subjects themselves if they were developmentally
able.
Subjects
In total, 20 patients with autism (18 males 2 females,
mean age ± standard deviation (SD) 8 ± 4 years, range 4
to 12 years) were enrolled through the Autism Research
and Treatment (ART) Center clinic from a sample
population consisting of children diagnosed with autism
spectrum disorder (ASD). The diagnosis of ASD was
confirmed in all subjects using the Autism Diagnostic
Interview-Revised (ADI-R) criteria [18], the Autism
Diagnostic Observation Schedule-Generic (ADOS-G)
criteria [19], and the Developmental, Dimensional and
Diagnostic Interview (3DI) [20]. All patients had autism
simplex, and all were negative for Fragile X. No patients
were on special diets or alternative treatments.
The control group was recruited from the Well Baby
clinic at King Khaled University Hospital (all male 16
males 4 females, mean age ± SD 7.5 ± 3.5 years, range 4
to 11 years). All participants were screened via parental
interview for current and past physical illness.
Exclusion criteria included presence of organic acid-
uria, dysmorphic features, a diagnosis of Fragile X or
other serious neurological (for example, seizures), or
psychiatric (for example, bipolar disorder) conditions, or
known medical conditions, including endocrine, cardio-
v a s c u l a r ,p u l m o n a r y ,l i v e r ,k i d n e yo ro t h e rm e d i c a l
disease.
Blood samples
After an overnight fast, patients underwent blood sam-
pling; 10 ml blood samples were collected on ice from
both groups in test tubes containing heparin as anticoa-
gulant. The samples were separated by centrifugation at
3000 rpm and 25°C for 10 minutes. The plasma was
removed and frozen at -80°C until analyzed.
Biochemical analyses
Assay of 5’-nucleotidase (5’-NT) and adenosine deaminase
(ADA) enzyme activities
5’-NT and ADA were assayed using commercial diagnos-
tic kits (BioQuant Inc., San Diego, CA, USA). The assays
are based on the enzymatic hydrolysis of 5’-inosinemono-
phosphate (5’-IMP) or the enzymatic deamination of
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which is converted to hypoxanthine by purine nucleoside
phosphorylase (PNP). Hypoxanthine is then converted to
uric acid and hydrogen peroxide (H2O2) by xanthine oxi-
dase (XOD). H2O2 is further reacted with N-ethyl N-(2-
hydroxy-3-sulfopropyl)-3-methylaniline (EHSPT) and 4-
aminoantipyrine (4-AA) in the presence of peroxidase
(POD) to generate a quinone dye, which was monitored
using a spectrophotometer set to the kinetic mode for 3
min, at 550 nm, with 1 min interval [21,22].
Measurement of glutamate dehydrogenase activity
For measurement of glutamate dehydrogenase activity, a
commercial kit (Randox Laboratories Ltd., Crumlin, Co.
Antrim, UK) was used. This is an optimized standard
method according to the recommendations of the
Deutsche Gesellschaft für Klinische Chemie. The sub-
strates a-xoglutarate and ammonium are converted to
g l u t a m a t ea n dw a t e rb yG D Hi nt h es a m p l e ,u s i n g
NADH as coenzyme. This procedure measures the non-
specific creep reaction through the change in NAD(H)
absorbance at 340 nm [23].
Measurement of ammonia and urea
Ammonia and urea were measured using diagnostic kits
(Randox Laboratories). The kits work in a similar way.
The ammonia in the sample combines with a-oxogluta-
rate and NADH in the presence of GDH to yield gluta-
mate and NAD
+. The corresponding decrease in
absorbance at 340 nm is proportional to the plasma
ammonia concentration [24]. Similarly, for urea, the
enzyme urease converts water and the urea in the sam-
ple to ammonia and carbon dioxide. Salicylate and
hypochlorite in the reagent react with the ammonium
ions to form a green complex (2,2-dicarboxylindophe-
nol), which is measured at 600 nm [25].
Measurement of creatine
The creatine assay used is an accurate, convenient mea-
sure of creatine for a variety of biological samples (Bio-
Vision Inc., Milpitas, CA, USA). In the assay, creatine is
enzymatically converted to sarcosine, which is then spe-
cifically oxidized to generate a product that converts a
colorless probe to an intensely red color (lmax =5 7 0
nm), and a strongly fluorescent (Ex/Em = 538/587 nm)
product. Creatine is therefore easily detected by either
colorimetric or fluorometric methods. The detection
range is 0.001 to 10 mmol/l creatine [26].
Measurement of nitric oxide
A colorimetric assay was used, which provides an accu-
rate, convenient measure of total nitrate/nitrite in a sim-
ple two-step process (Biovision). The first step is the
conversion of nitrate to nitrite by nitrate reductase. The
reagents react with nitrite only, and not nitrate. The sec-
ond step uses Griess reagents to convert nitrite to a
deep purple azo compound, and the amount of the azo
chromophore accurately reflects nitric oxide amount in
samples. The detection limit of the assay is approxi-
mately 0.1 nmol nitrite/well, or 1 μmol/l [27].
Assay of GABA
Quantitative determination of GABA was performed
using ELISA immunoassay kit (ALPCO Diagnostics,
Salem, NH, USA). An aliquot (300 μL) of each sample
type (diluted standard, control or undiluted samples)
was placed in each well, then 300 μl of the diluent was
added. The plate was covered with adhesive foil and agi-
tated on a shaker at 600 rpm for 30 minutes at room
temperature (20 to 25°C). Two washing cycles were per-
formed, through incubation with 1 ml of I-buffer for 5
min at RT (20-25°C) on a shaker, after which 250 μlo f
elution buffer was placed into the appropriate wells of
the extraction plate, which was covered and placed on
the shaker for 10 minutes. Next, 100 μlo fe a c he x t r a c t
was used for derivatization. NaOH (10 μl) was added
into each well, followed by 50 μl of the equalizing
reagent (freshly prepared before each assay) and the
plates shaken for 1 minute at 600 rpm. Then, 10 μlo f
the D-reagent was added into each well, and the plate
incubated for 2 hours at room temperature on a shaker.,
after which 150 μl of the buffer supplied with the kit
(Q-buffer) was added into each well, and the plate incu-
b a t e df o r1 0m i na tr o o mt e m p e r a t u r ea t6 0 0r p m .
From each well, 25 μl was removed and transferred to
the GABA microtiter strips to start the ELISA. To that,
50 μl of GABA antiserum was added, mixed, covered,
and incubated for 2 hours at RT on a shaker. After 3
washings with 300 μl wash buffer, 100 μlo fe n z y m e
conjugate was added to the dry wells, covered, and incu-
bated for 30 min again at RT with shaking. After
another 3-washings and drying step, 100 μlo fs u b s t r a t e
(TMB) was added with incubation for 20-30 min at RT
on a shaker. Finally, 100 μlo ft h es t o ps o l u t i o nw a s
added with shaking, and the absorbance was read within
10 minutes, using a microplate reader set to 450 nm
and a reference wavelength between 620 nm and 650
nm.
Measurement of glutamate and glutamine levels
Glutamate and glutamine levels were assessed using an
HPLC method [28]. Plasma samples (0.1 ml) were
mixed with 5 μl mercaptoethanol and allowed to stand
for 5 minutes at room temperature, then precipitated
with ice-cold methanol while being vortexed. Tubes
were allowed to stand for 15 minutes in an ice bucket
before samples were separated by centrifugation (5000
rpm for 15 minutes) and the supernatant was collected.
The efficiency of the protein precipitation step was
assessed by Bradford’s dye-binding method [29]. The
protein-free supernatants were processed immediately
for HPLC analysis of the two amino acids.
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Statistical Program for Social Sciences (SPSS) (SPSS Inc.,
Chicago, IL, USA) was used for all analyses. Results
were expressed as mean ± SD. All statistical compari-
sons were made by means of Student’s t-test. P <0 . 0 5
was considered significant. The data was also illustrated
using normal distribution, mean, and percentage for
each parameter and group. Pearson’s correlation coeffi-
cient was used to find a correlation between the mea-
sured parameters. Generally, positive or negative
correlations above 0.80 are considered very high. The
receiver operating characteristic (ROC) curve, a funda-
mental tool for biomarker evaluation, was performed
using the same computer program. In a ROC curve, the
true positive rate (sensitivity) is plotted in function of
the false positive rate (100-specificity) for different cut-
off points of a parameter. Each point on the ROC curve
represents a sensitivity/specificity pair corresponding to
a particular decision threshold. The area under the ROC
curve is a measure of how well a parameter can distin-
guish between patients with autism and control subjects.
Results
We compared the levels of the various chemicals and the
activities of some enzymes in the plasma of autistic and
control groups (Table 1; Figure 1; Figure 2; Figure 3).
Of these, only creatine, ADA and 5’-NT were signifi-
cantly different between the autistic group and the con-
trol group (Table 1, Figure 1, Figure 2). The autistic
group had an increase in nitric oxide and ammonia of
9.82% and 19.75%, respectively, compared with the con-
trol group, but this was non-significant. There was also
a decrease in levels of GDH and urea of 18.75% and
8.31% respectively, in the autistic group compared with
the control group, but again, this was non-significant.
T h e r ew a sam a r k e di n c r e a s ei nb o t hG A B Aa n dG l u :
Gln levels in patients with autism compared with con-
trols (Table 1; Figure 2; Figure 3H, I] Of 25 patients
with autism, 22 had GABA levels of 60 ng/ml or higher,
whereas only 5 of 16 controls had levels of 54 ng/ml or
higher. Overall, there was a 43% increase in GABA in
patients with autism compared with controls (Figure 2).
There was a marked increase in the Glu:Gln ratio, with
all (20/20; 100%) of patients with autism having ratios
greater than 1.25, whereas all the controls had ratios of
less than 0.55; overall, there was an increase of 196.18%
increase in the Glu:Gln ratio in patients with autism
compared with controls (Figure 2).
When Pearson correlation coefficients were calculated,
it was apparent that ADA was negatively correlated with
Cr and NH3 (P <0 . 0 3a n dP < 0.05, respectively),. The
Glu:Gln ratio was positively correlated with creatine, 5’-
NT and GABA, and negatively correlated with ADA
only (Table 2; Figure 4)
Using ROC analysis, the highest values for specificity
and sensitivity were found for the Glu:Gln ratio, GABA,
5’-NT and Cr (Table 3; Figure 5A, B).
Discussion
Despite the fact that neurological disorders can be caused
by many different primary defects, they often produce
similar impairments in cellular energy metabolism in the
Table 1 Mean ± SD of the measured chemicals in plasma
of patients with autism compared with age-matched
controls.
a
Group Mean ± SD P value
Cr, nmol/ul Control 0.47 ± 0.06 0.000
Autistic 0.54 ± 0.06
NO, nmol/ul Control 0.036 ± 0.00 0.084
Autistic 0.040 ± 0.01
GDH, U/l Control 1.58 ± 0.87 0.311
Autistic 1.28 ± 0.93
ADA, U/l Control 20.47 ± 11.90 0.048
Autistic 14.56 ± 4.39
5’-NT, U/l Control 9.31 ± 1.82 0.001
Autistic 10.97 ± 0.87
NH3, mg/dl Control 1.19 ± 0.46 0.230
Autistic 1.43 ± 0.71
Urea, mmol/l Control 5.03 ± 0.96 0.382
Autistic 4.66 ± 1.62
GABA, ng/ml Control 55.29 ± 4.15 0.023
Autistic 79.09 ± 16.77
Glu, μmol/l Control 111.9 ± 4.63 0.001
Autistic 152.8 ± 16.77
Gln, μmol/l Control 241.82 ± 13.29 0.001
Autistic 111.34 ± 5.69
Glu:Gln Control 0.46 ± 0.03 0.001
Autistic 1.37 ± 0.06
aAbbreviations: 5’-NT, 5’-nucleotidase; ADA, adenosine deaminase; Cr, creatine;
GABA, gamma-aminobutyric acid; GDH, glutamate dehydrogenase; Gln,
glutamine; Glu, glutamate; NH3, ammonia; NO, nitric oxide.
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Figure 1 Percentage decrease in glutamate dehydrogenase
(GDH), adenosine deaminase (ADA) and urea in patients with
autism compared with controls.
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Page 4 of 11brain. In these instances, intracellular concentration of
ATP is decreased, resulting in cytosolic accumulation of
Ca
2+ and generation of reactive oxygen species (ROS).
Ca
2+ and ROS, in turn, trigger apoptotic or necrotic cell
death. For many of these disorders, impairments of brain
Cr metabolism have also been described, including
decreases in total Cr concentration, PCr concentration,
CK activity, and/or creatine transporters (CrT) content
[30-32]. Similarly, knockout mice lacking the brain cyto-
solic and mitochondrial isoenzymes of CK displayed a
slightly increased Cr concentration, but no PCr in the
brain. These mice had decreased weight gain and reduced
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Figure 2 Percentage increase in creatine (Cr), nitric oxide (NO),
5’-nucleotidase (5’-NT), ammonia (NH3), gamma-aminobutyric
acid (GABA), and glutamate:glutamine (Glu:Gln) ratio in
patients with autism compared with controls.
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Figure 3 Normal distribution for the various measured parameters in the control and autistic groups. The scale of the X axis is different
for the two groups, because of the marked differences between them.
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abnormalities, and impaired learning capacity [32].
In this study, we found that patients with autism from
Saudi Arabia had raised levels of plasma Cr compared
with age-matched controls (Table 1; Figure 2; Figure 3).
Increased plasma Cr could be due to defective Cr trans-
port to the brain, a suggestion supported by recent work
by Kara et al. [33], in which they showed that cerebral
Cr deficiency (as detected in vivo by magnetic resonance
spectroscopy (MRS) of the brain) and specific distur-
bances in metabolites of Cr metabolism in body fluids
was linked to mental retardation, expressive speech and
language delay, epilepsy, developmental delay, and autis-
tic behavior [33]. In addition, autistic features were seen
Table 2 Pearson correlation (R) between the measured
parameters
a
Parameters RP value
ADA and Cr -0.351
b 0.027
ADA and NH3 -0.327
b 0.042
ADA and Glu:Gln -0.334
b 0.038
Glu:Gln and Cr 0.576
a 0.000
Glu:Gln and 5’-NT 0.506
a 0.001
Glu:Gln and GABA 0.657
a 0.000
aAbbreviations: 5’-NT, 5’-nucleotidase; ADA, adenosine deaminase; Cr, creatine;
GABA, gamma-aminobutyric acid; Gln, glutamine; Glu, glutamate; NH3,
ammonia.
bNegative correlation.
cPositive correlation.
    
 
 
               
 
Figure 4 Pearson correlations between the measured parameters showing the best-fit line curve with either positive or negative
correlations.
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(GAMT) deficiency as an inborn error of Cr biosynth-
esis. The diagnosis of GAMT deficiency is based on
excessive amounts of guanidinoacetate in body fluids,
and decreased levels of Cr/PCr in the brain [34,35]. Our
speculated decrease of brain Cr occurring concomitantly
with raised plasma Cr in Saudi patients with autism is
also in line with the work of Battini et al. [36] in which
1H-MRS disclosed brain Cr depletion in 2-year-old child
who presented with psychomotor and language delay,
and autistic-like behavior.
NO has been recognized as a biological neural messen-
ger molecule, although it is best known as a toxic reactive
free radical in the CNS. NO or NO-derived nitrogen
oxides must interact with and modify neuromodulators,
especially in patients with autism compared with con-
t r o l s ,w h i c hi n d i c a t e sap o s s i b l er o l eo fn i t r i co x i d e
synthase in the pathogenesis of autism [37]. Increased
oxidant end-products produced by the reactions of NO
with other free radicals may possibly contribute to the
psychopathology of autism because of the preferential
vulnerability of the brain of patients with autism to oxi-
dative injury, as shown in a previous Saudi study [5].
Although we did not find a significant increase in NO in
the Saudi boys with autism in the present study, the level
was almost 10% higher than that in controls, thus there is
still a suggestion that NO might contribute to the patho-
genesis of autism. The lack of significance might be attri-
butable to the finding in a recent study by Al-Yafee et al.
who reported a significant increase in peroxidoxins,
which are very efficient scavengers of NO [38].
ADA (EC 3.5.4.4) is an enzyme catalyzing hydrolytic
deamination of either adenosine or deoxyadenosine to
inosine and deoxyinosine, respectively. Because of the
irreversibility of the reaction catalyzed by ADA, this
enzyme reaction seems to be one of the rate-limiting
steps in adenosine degradation [39]. Detoxification of
adenosine and deoxyadenosine is important because they
are toxic to cells in high concentrations. Several mechan-
isms for this toxicity have been proposed. One possible
explanation is that high concentrations of adenosine and
deoxyadenosine cause dATP accumulation in the cell;
dATP is a strong inhibitor of ribonucleotide reductase
and causes some aberrations in DNA synthesis [40].
Adenosine mediates its actions through the activation
of specific G-protein-coupled receptors (adenosine
Table 3 Receiver operating characteristic analysis of the
measured parameters showing area under the curve
(AUC), specificity and sensitivity of each.
Parameter AUC Best cut-off value Sensitivity, % Specificity, %
Cr 0.812 0.511 75.0 85.0
NO 0.770 0.036 95.0 55.0
GDH 0.608 1.084 55.0 68.0
ADA 0.624 16.226 80.0 55.0
5’-NT 0.787 10.247 85.0 68.0
NH3 0.586 2.107 25.0 100.0
Urea 0.637 5.196 80.0 50.0
GABA 0.866 61.74 85.0 100.0
Glu:Gln 1.000 0.906 100.0 100.0
aAbbreviations: 5’-NT, 5’-nucleotidase; ADA, adenosine deaminase; Cr, creatine;
GABA, gamma-aminobutyric acid; GDH, glutamate dehydrogenase; Gln,
glutamine; Glu, glutamate; NH3, ammonia; NO, nitric oxide.
 
 
 
 
 
 
 
 
 
 
Figure 5 Receiver operating characteristic (ROC) curve of (A) creatine (Cr), nitric oxide (NO), 5’-nucleotidase (5’-NT), ammonia (NH3),
gamma-aminobutyric acid (GABA), and glutamate:glutamine (Glu:Gln) ratio and (B) of glutamate dehydrogenase (GDH), adenosine
deaminase (ADA), and urea in autistic group.
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Page 7 of 11receptors; ARs), of which four subtypes have been iden-
tified (A1R, A2AR, A2BR and A3R) [41]. These recep-
tors have distinctive pharmacological profiles, tissue
distributions and effector-coupling mechanisms, and
their functioning has been extensively studied in the
CNS [42]. Interestingly, A1R and A2AR are largely
responsible for the central effects of adenosine [43].
A2AR is mostly coupled to G-proteins in the peripheral
systems, and mediates its effects predominantly through
activation of adenylyl cyclase, which in turn converts
ATP into cAMP. It is well known that low concentra-
tions of adenosine activate predominantly A1R, which
inhibits glutamate release. High concentrations of ade-
nosine activate A2AR, which, by means of the A1R/
A2AR intramembrane interaction, antagonizes A1R
function, therefore facilitating glutamate release [44].
Moreover, the modulatory effects of adenosine on dopa-
mine systems have been investigated, in view of their
relevance to human disorders such as schizophrenia and
Parkinson’s disease. Antagonistic adenosine-dopamine
interactions have been widely reported, showing that
adenosine can inhibit several effects of dopamine in the
cerebral cortex and basal ganglia [45]. Therefore, a pos-
sible relationship between the losses of adenosine home-
ostasis due to the currently reported reduced activity of
ADA, and the impairment of neurotransmitter profile is
suggested in patients with autism. This is also supported
by the findings of our most recent work in which we
reported low plasma and high brain serotonin and dopa-
mine concentration in patients with autism compared
with control subjects [46].
Based on these results, it seems likely that tight con-
trol of adenosine levels could play an important role in
brain development and neural plasticity [47], and that
any dysfunction in homeostatic control of adenosine, an
important modulator of the brain immune system, could
upset the balance between pro-inflammatory and anti-
inflammatory cytokines, which is crucial for normal
brain development [48]. Together, these findings sup-
port a contribution of the decreased activity of ADA
reported in the present study to the dysfunction in nor-
mal adenosine homeostasis in Saudi patients with aut-
ism during prenatal and perinatal brain development.
The decreased ADA activity recorded in the present
study is in good agreement with an earlier study by
Stubbs et al. who reported reduced activity of ADA in
subjects with autism compared with that in healthy con-
trols, patients with mental retardation, and patients with
cerebral palsy [49]. Lower ADA activity in patients with
autism might also be related to the increased levels of
interleukin-6 and tumor necrosis factor-a,a n dt h e
impaired Ca
2+ and K
+ homeostasis that were reported
from two studies using the same investigated autistic
samples [50,51].
It is well known that 5’-NT activity is increased in
response to abnormal accumulation of some nucleotide
substrates [52]. In the present study, the significant
increase in 5’-NT activity in patients with autism com-
pared with control subjects might be related to the sig-
nificantly lower ADA activity recorded in the same
samples, as lower ADA could lead to the accumulation
of adenosine and AMP. This suggestion is supported by
previous work from Page et al. [53], who identified four
unrelated patients in whom developmental delay, sei-
zures, ataxia, recurrent infections, speech deficit, and an
unusual autistic behavioral phenotype were associated
with increased activity of 5’-NT and more recent work
by Page [54] showing that 5’-NT superactivity is one of
the most important metabolic defects associated with
autistic symptoms.
We found that GABA was significantly higher in the
plasma of Saudi patients with autism, with a 43%
increase compared with controls (Table 1; Figure 2).
This is in good agreement with the previous work of
Dhossche and Rout [55], who reported that children
with autism have increased plasma GABA levels. This
increase may also be associated with reduced cerebral
GABA, which might be the result of a reduced number
of neurons expressing this neurotransmitter [56,57].
This suggestion is supported by the work of Hollander
et al. in which they reported that inhibition of the cata-
bolic enzymes of GABA using divalproex was effective
in treating boys with autism [58]. The patients were
described as having affective instability (for example,
they were impulsive and aggressive) and retrospective
analysis suggested that 10 of the patients (72%) had
improved behavior after divalproex treatment, which
might be due to increases in GABA in the brain.
One distinctive strategy that serves to accomplish the
marked stratification of brain glutamate levels is the
Glu-Gln cycle. To minimize the risk of excitotoxicity,
the intrasynaptic glutamate must be kept at a very low
level. At the same time, neurons require a steady supply
of precursors to replenish the glutamate lost via oxida-
tive processes. The Glu-Gln cycle in the brain serves to
control the levels of glutamate, and to shuttle nitrogen
between astrocytes and neurons. Under basal conditions,
glutamate is metabolized in astrocytes by the GS reac-
tion rather than by GDH, favoring glutamine formation
[59,60]. In the present study, the significant increase in
the Glu:Gln ratio that we found in patients with autism
compared with controls suggest that the Glu-Gln cycle
was greatly affected in these patients. This could be
related to the increased levels of ammonia and the
marked reduction in urea concentration reported in the
present study.
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The use of potential biomarkers that indicate specific
mechanisms of disordered neurodevelopment should
help to identify meaningful subtypes of autism and tailor
treatment or prevention strategies. A number of the
parameters we investigated had decreased or increased
levels in the patients with autism compared with the
age-matched control subjects. Glutamate excitotoxicity
is probably the final common pathway or mechanism
through which impaired nitrogen metabolism might be
involved in the etiology of autism. The increased Glu:
Gln ratio and the positively correlated abnormal levels
of Cr, GABA, and 5’-NT might be useful diagnostic
markers for autism (Figure 6). We have outlined the
relationship of glutamate and glutamine to most of the
measured parameters (Figure 7), and illustrated the
interactions between the key metabolites and pathways
that we suggest might play a role in the pathophysiology
of autism.
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